Impact BioMedical, Inc. (IBO) — Strategic Asset Allocation Index

Latest as of March 2025: 0.2%

Impact BioMedical, Inc. (IBO) has a Strategic Asset Allocation Index of 0.2% as of March 2025. Strategic assets (PP&E of $16.00K plus long-term investments of $-) total $16.00K, measured against net assets of $6.81 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check Impact BioMedical, Inc. (IBO) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

SAAI

0.2%
Strategic Assets / Net Assets

Strategic Assets

$16.00K
PP&E + LT Investments

PP&E

$16.00K
USD

Net Assets

$6.81 Million
USD

Impact BioMedical, Inc. Strategic Asset Allocation Index (2021–2024)

This chart shows how Impact BioMedical, Inc.'s Strategic Asset Allocation Index has evolved across 4 annual periods from 2021 to 2024. As of March 2025, the index stands at 0.2%, representing strategic assets of $16.00K against net assets of $6.81 Million USD. See financial flexibility index of Impact BioMedical, Inc. to measure the company's free cash flow as a share of total liabilities.

Annual Strategic Asset Allocation Index for Impact BioMedical, Inc. (2021–2024)

The table below presents the year-by-year Strategic Asset Allocation Index for Impact BioMedical, Inc. from 2021 to 2024, covering 4 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see IBO market cap overview.

Year SAAI Strategic Assets (USD) PP&E LT Investments Net Assets Change (pp)
2024 0.2% $17.00K $17.00K $- $7.24 Million ▼ -0.8 pp
2023 1.0% $287.00K $287.00K $0.00 $28.26 Million ▼ -2.2 pp
2022 3.2% $1.06 Million $276.00K $782.00K $32.67 Million ▼ -160.4 pp
2021 163.6% $4.82 Million $- $4.82 Million $2.94 Million
pp = percentage points